NCT06804772进行中（未招募）不适用
A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α to Improve the Signs of Aging, Part 2
Victoria Collotta2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2024年12月3日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- Change in appearance of fine lines/wrinkles as evaluated by the Principal Investigator using a scale from 0-9
研究概览
简要总结
A clinical study with approximately 15 subjects, aged 35-65 years of age, who must have crow's feet and at least one other type of facial fine lines/wrinkles in order to evaluate the efficacy of Activated Silk™ 27P-α to improve the signs of aging, by comparing to a placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 35 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy individuals, between the ages of 35 - 65 years of age, with no known medical conditions that interfere with study participation, are the priority.
- •Subject has signed a written Informed Consent prior to Day -
- •100% of subjects have crow's feet and at least one of the following: forehead lines/wrinkles (e.g. vertical lines between eyebrows, horizontal lines above the eyebrow), marionette lines, nasolabial folds.
- •50% of subjects have self-perceived sensitive skin.
- •20% of the subjects are not 100% Caucasian.
排除标准
- •Subject is pregnant, nursing, or planning to become pregnant.
- •Subject is currently using medication likely to affect the response to investigational formulation.
- •Subject had a fever in the last 12 hours prior to the start of the study.
- •Subject has a pacemaker or significant medical history of hepatic, renal, cardiac, pulmonary, digestive, hematological, neurological, locomotor or psychiatric disease; cancer; multiple sclerosis; high blood pressure; thrombosis; phlebitis; insulin-dependent diabetes; or any such related medical condition(s) that may interfere with the completion of the study.
- •The Subject used a form of retinol on their face in the past six months.
- •The Subject used any prescription skincare products on their face in the last six months.
- •The Subject has received any laser, chemical peel, or other facial resurfacing treatment such as microdermabrasion, dermablading or microneedling in the past four weeks.
- •The Subject received Botox, Dysport, other muscle relaxers or injectable skin fillers in the face during the past six months.
- •Subject has a known allergy or sensitivity to any ingredient in the aqueous skincare formulation provided for their use in the trial .
- •Subject is currently participating in another study utilizing facial products.
- •Subject is blind, visually impaired or decisionally impaired.
结局指标
主要结局
Change in appearance of fine lines/wrinkles as evaluated by the Principal Investigator using a scale from 0-9
时间窗: Day 0 to Day 28
Change in appearance of fine lines/wrinkles for subjects treated with Investigational Facial Serum #3 at Day 28 vs. Day 0
次要结局
- Change in appearance of skin characteristics(Day 0 to Day 28)
研究者
Victoria Collotta
General Manager, Branded Products, Principal Investigator
Evolved By Nature
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Clinical Trial to Evaluate the Efficacy and Safety of MegaCarti® in Knee Cartilage DefectsOsteoarthritis, KneeNCT06249828L&C Bio61
已完成
不适用
Evaluation of the Effectiveness of the PiQo4 System for Reduction of Infra-orbital PigmentationPOHNCT04214873Focus Medical, LLC8
已完成
不适用
Single arm pilot study to evaluate the effectiveness of oolong tea in upper gastrointestinal endoscopyPerson planning screening upper gastrointestinal endoscopyJPRN-UMIN000040070Osaka Center for Cancer and Cardiovascular Disease Prevention5
终止
2 期
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic AnemiaAgedHemoglobinsAnemiaNCT00210795Johnson & Johnson Pharmaceutical Research & Development, L.L.C.12
终止
2 期
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic AnemiaAgedHemoglobinsAnemiaNCT00228995Johnson & Johnson Pharmaceutical Research & Development, L.L.C.9